DOI: 10.1101/468306
Funding statement: This project was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), grant UL1TR000427, and by the University of Wisconsin-Madison Office of the Chancellor and the Vice Chancellor for Research and Graduate Education with funding from the Wisconsin Alumni Research Foundation. B.F.D. was supported by an NLM training grant to the Computation and Informatics in Biology and Medicine Training Program [NLM 5T15LM007359]. This research was also supported by the NIH grants R01 AG054047, R01 AG27161, and P2C HD047873, Helen Bader Foundation, Northwestern Mutual Foundation, Extendicare Foundation, and State of Wisconsin. C.C. was supported by NIH grants P01 AG003991, R01 AG057777, R01 AG044546, RF1 AG053303, RF1 AG058501, and U01 AG058922. T.J.H. was supported by NIH grants R01 AG059716, R21 AG059941, and K01 AG049164. The authors thank the University of Wisconsin Madison Biotechnology Center Gene Expression Center for providing Illumina Infinium genotyping services. We thank the International Genomics of Alzheimer's Project (IGAP) for providing summary results data for these analyses. The investigators within IGAP contributed to the design and implementation of IGAP and/or provided data but did not participate in analysis or writing of this report. IGAP was made possible by the generous participation of the subjects and their families. The i-Select chips were funded by the French National Foundation on Alzheimer's disease and related disorders. EADI was supported by the LABEX (laboratory of excellence program investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2, and the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 503480), Alzheimer's Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z), and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia (CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA grant R01 AG033193 and the NIA AG081220 and AGES contract N01–AG–12100, the NHLBI grant R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 AG016976, and the Alzheimer's Association grant ADGC–10–196728. We thank contributors who collected samples used in this study, as well as patients and their families, whose help and participation made this work possible; Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689-01). We are also grateful for ADGC and its investigators for providing GWAS summary statistics for various AD phenotypes. The full acknowledgement to ADGC is included in the supplementary material. Summary statistics for cognitively defined subgroups was generated with support from R01AG042437. Data were from the Adult Changes in Thought (ACT) study, the Religious Orders Study (ROS), the Rush Memory and Aging Project (MAP), the Alzheimer's Disease Neuroimaging Initiative (ADNI), and the University of Pittsburgh Alzheimer's Center. ACT data collection was supported by U01 AG006781. ACT genotyping was supported by U01 HG006375. Cerebellum samples for genotyping for some ACT samples were prepared with support from P50 AG005136. ADNI data collection and genotyping were supported by U01 AG024904. Data collection and sharing was funded by U01 AG024904 and W81XWH-12-2- 0012. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & | Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. MAP data collection and genotyping were supported by R01 AG017917. Additional genotyping was supported by Kronos, Zinfandel, and U01 AG032984. ROS data collection and genotyping were supported by P30 AG10161, R01 AG15819, and R01 AG30146. Additional genotyping was supported by Kronos, Zinfandel, and U01 AG032984. PITT data collection were funded by P50 AG05133, R01 AG030653, and R01 AG041718.
Annotated funders:
funder_name: NIH National Center for Advancing Translational Sciences (NCATS)
awards: award_ids: UL1TR000427
award_title: Clinical and Translational Science Award (CTSA) program
funder_name: University of Wisconsin-Madison Office of the Chancellor and the Vice Chancellor for Research and Graduate Education
funder_name: Wisconsin Alumni Research Foundation
funder_name: NLM
awards: award_ids: 5T15LM007359
award_title: Computation and Informatics in Biology and Medicine Training Program
funder_name: NIH
awards: award_ids: R01 AG054047
R01 AG27161
P2C HD047873
P01 AG003991
R01 AG057777
R01 AG044546
RF1 AG053303
RF1 AG058501
U01 AG058922
R01 AG059716
R21 AG059941
K01 AG049164
R01 AG033193
U01 AG032984
U24 AG021886
U01 AG016976
U24-AG041689-01
R01AG042437
U01 AG006781
U01 HG006375
P50 AG005136
U01 AG024904
R01 AG017917
P30 AG10161
R01 AG15819
R01 AG30146
P50 AG05133
R01 AG030653
R01 AG041718
funder_name: Helen Bader Foundation
funder_name: Northwestern Mutual Foundation
funder_name: Extendicare Foundation
funder_name: State of Wisconsin
funder_name: French National Foundation on Alzheimer's disease and related disorders
funder_name: LABEX (laboratory of excellence program investment for the future)
awards: award_title: DISTALZ grant
funder_name: Inserm
funder_name: Institut Pasteur de Lille
funder_name: Université de Lille 2
funder_name: Lille University Hospital
funder_name: Medical Research Council
awards: award_ids: 503480
funder_name: Alzheimer's Research UK
awards: award_ids: 503176
funder_name: Wellcome Trust
awards: award_ids: 082604/2/07/Z
funder_name: German Federal Ministry of Education and Research (BMBF)
awards: award_ids: 01GI0102
01GI0711
01GI0420
award_title: Competence Network Dementia (CND)
funder_name: NIH/NIA
awards: award_ids: R01 AG033193
U01 AG032984
U24 AG021886
U01 AG016976
funder_name: NIA
awards: award_ids: AG081220
funder_name: AGES
awards: award_ids: N01–AG–12100
funder_name: NHLBI
awards: award_ids: R01 HL105756
funder_name: Icelandic Heart Association
funder_name: Erasmus Medical Center
funder_name: Erasmus University
funder_name: Alzheimer's Association
awards: award_ids: ADGC–10–196728
funder_name: National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS)
awards: award_ids: U24-AG041689-01
funder_name: National Institute of Biomedical Imaging and Bioengineering
funder_name: AbbVie
funder_name: Alzheimer's Drug Discovery Foundation
funder_name: Araclon Biotech
funder_name: BioClinica, Inc.
funder_name: Biogen
funder_name: Bristol-Myers Squibb Company
funder_name: CereSpir, Inc.
funder_name: Cogstate
funder_name: Eisai Inc.
funder_name: Elan Pharmaceuticals, Inc.
funder_name: Eli Lilly and Company
funder_name: EuroImmun
funder_name: F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
funder_name: Fujirebio
funder_name: GE Healthcare
funder_name: IXICO Ltd.
funder_name: Janssen Alzheimer Immunotherapy Research & Development, LLC.
funder_name: Johnson & | Johnson Pharmaceutical Research & Development LLC.
funder_name: Lumosity
funder_name: Lundbeck
funder_name: Merck & Co., Inc.
funder_name: Meso Scale Diagnostics, LLC.
funder_name: NeuroRx Research
funder_name: Neurotrack Technologies
funder_name: Novartis Pharmaceuticals Corporation
funder_name: Pfizer Inc.
funder_name: Piramal Imaging
funder_name: Servier
funder_name: Takeda Pharmaceutical Company
funder_name: Transition Therapeutics
funder_name: Canadian Institutes of Health Research
funder_name: Foundation for the National Institutes of Health
funder_name: Northern California Institute for Research and Education
funder_name: Alzheimer's Therapeutic Research Institute at the University of Southern California
funder_name: Laboratory for Neuro Imaging at the University of Southern California
funder_name: Kronos
funder_name: Zinfandel